Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
Authors
Keywords
Adverse events, Diabetes mellitus, Hypoglycemia, HbA1c, Drug administration, Cost-effectiveness analysis, Type 2 diabetes, Drug therapy
Journal
PLoS One
Volume 11, Issue 11, Pages e0167190
Publisher
Public Library of Science (PLoS)
Online
2016-11-23
DOI
10.1371/journal.pone.0167190
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin
- (2015) Man-man Wang et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Improving diabetes medication adherence: successful, scalable interventions
- (2015) Leah Zullig et al. Patient Preference and Adherence
- Determinants of adherence to diabetes treatment
- (2015) Amy T. Larkin et al. Journal of Diabetes
- Assessment of the Relative Effectiveness and Tolerability of Treatments of Type 2 Diabetes Mellitus: A Network Meta-analysis
- (2014) Elias Zintzaras et al. CLINICAL THERAPEUTICS
- The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes
- (2014) S. Lane et al. CURRENT MEDICAL RESEARCH AND OPINION
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
- (2014) N Waugh et al. HEALTH TECHNOLOGY ASSESSMENT
- Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
- (2014) Chun-Jun Li et al. Diabetology & Metabolic Syndrome
- Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: A cohort study of 8486 primary-care patients
- (2013) J. Bodegard et al. DIABETES & METABOLISM
- Prevalence and Control of Diabetes in Chinese Adults
- (2013) Yu Xu JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation
- (2012) Eberhard Standl et al. Diabetes & Vascular Disease Research
- The Impact of Treatment Noncompliance on Mortality in People With Type 2 Diabetes
- (2012) C. J. Currie et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA
- (2012) Lan Gao et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus
- (2011) Deanna S. Kania et al. CLINICAL THERAPEUTICS
- Effective Control of Postprandial Glucose Level through Inhibition of Intestinal Alpha Glucosidase byCymbopogon martinii(Roxb.)
- (2011) Varsha Ghadyale et al. Evidence-based Complementary and Alternative Medicine
- A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes
- (2010) P. McEwan et al. DIABETES OBESITY & METABOLISM
- Assessing the Relationship between Computational Speed and Precision
- (2010) Phil McEwan et al. PHARMACOECONOMICS
- The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus
- (2009) F. Xavier Pi-Sunyer POSTGRADUATE MEDICINE
- Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China
- (2008) James L. Palmer et al. ADVANCES IN THERAPY
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2008) D. M. Nathan et al. DIABETES CARE
- Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
- (2008) C. Pan et al. DIABETIC MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now